From: Co-expression of TIMP-1 and its cell surface binding partner CD63 in glioblastomas
 | Baseline model | CD63 | |||
---|---|---|---|---|---|
 | Patients (n) | HR (95% CI) | P-value | HR (95% CI) | P-value |
Age (continuous) | 74 | 1.01 (0.98–1.03) | 0.70 | 1.00 (0.98–1.03) | 0.71 |
Sex | |||||
 Male | 47 | 1.00 |  | 1.00 |  |
 Female | 27 | 0.82 (0.49–1.37) | 0.44 | 0.76 (0.45–1.29) | 0.31 |
TIMP-1 score | |||||
 0–5 | 12 | 1.00 |  | 1.00 |  |
 6–7 | 26 | 5.05 (2.14–11.9) | < 0.001 | 5.06 (2.13–12.0) | < 0.001 |
 8–9 | 24 | 3.33 (1.43–7.71) | 0.005 | 3.27 (1.38–7.76) | 0.007 |
 10–12 | 12 | 5.18 (1.96–13.6) | 0.001 | 4.66 (1.74–12.5) | 0.002 |
CD63 score | |||||
 0–6 | 22 | – | – | 1.00 |  |
 7–8 | 29 | – | – | 1.09 (0.58–2.06) | 0.79 |
 9–12 | 23 | – | – | 1.51 (0.78–2.91) | 0.22 |